1. MatrisianLM AizenbergR RosenzweigA.The alarming rise of pancreatic cancer deaths in the United States: why we need to stem the tide today. Pancreatic Cancer Action Network.https://b0279e4bd99455edf432‐0e17ed1620a25e0243e5f59c02373f7f.ssl.cf2.rackcdn.com/wp‐content/uploads/2013/01/incidence_report_2012_executive_summary.pdf. Accessed May 25 2022.
2. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
3. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
4. HALO 109–301: a randomized, double‐blind, placebo‐controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab‐paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)‐high metastatic pancreatic ductal adenocarcinoma (mPDA);Tempero M;J Clin Oncol,2020
5. Boston Biomedical Inc announces update on phase 3 CanStem111P study of napabucasin in patients with metastatic pancreatic cancer following interim analysis.www.prnewswire.com/news‐releases/boston‐biomedical‐inc‐announces‐update‐on‐phase‐3‐canstem111p‐study‐of‐napabucasin‐in‐patients‐with‐metastatic‐pancreatic‐cancer‐following‐interim‐analysis‐300879064.html. Accessed May 13 2022.